Nebulized Bronchodilators for COPD Exacerbations
This study is looking at how well two nebulized medications, Revefenacin and Formoterol, work for people who come to the emergency department (ED) with a sudden worsening of their COPD (ECOPD). These are long-acting bronchodilators, meaning they help open your airways for a longer time. The study compares them to the usual treatment, which is nebulized Albuterol and Ipratropium, which are short-acting bronchodilators. Researchers want to see if the new combination is just as good at easing your breathing difficulties, measured by the Modified Borg Dyspnea Scale. You can join if you are at least 40 years old, have a history of COPD, and are in the ED for an ECOPD.
- Study design
- This is an interventional study planning to enroll 280 participants. It compares different nebulized medications for COPD exacerbations.
- What's involved
- Participants will receive study medications via nebulizer daily for up to 7 days. Your breathing difficulties will be measured during this time.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your breathing difficulties will be monitored from when you join the study through Day 7 (the end of treatment).
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Patients Presenting to the Emergency Department With Acute Exacerbation of COPD (ECOPD)
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Difference in Modified Borg Dyspnea Scale scores between groupsFrom enrollment through Day 7 (end of treatment)
This is a scale asks the subject to rate the difficulty of their breathing. It starts at number 0 where breathing is causing no difficulty at all and progresses through to number 10 where breathing difficulty is maximal. This will be recorded prior to dosing twice a day between 7 and 9 am \& pm. Scores from Group 1 and Group 2 will be averaged and compared.